CD274 and renal cell carcinoma: In our meta-analysis, we provided pooled estimates of outcomes in RCC patients with sarcomatoid features randomized to anti PD-1/PDL-1 agents vs. sunitinib and obtained a pooled PFS-HR of 0.57 and pooled OS-HR of 0.56.